Osimertinib is a prescription-only kinase inhibitor used for certain EGFR-mutated non-small cell lung cancers.[1]
This directory currently includes 14 products represented by their manufacturers or suppliers as containing osimertinib. It is not a complete global list, and regulatory status may differ by product and country.[3]
Availability enquiries are handled by Medicine for World. Submission of an enquiry does not confirm regulatory eligibility, supply or delivery. Ownership and commercial disclosure
Osimertinib is the generic (international non-proprietary) name of an oral kinase inhibitor that acts on the epidermal growth factor receptor (EGFR). It was first approved in the United States in 2015 under the brand name Tagrisso, marketed by AstraZeneca, and was authorised in the European Union in February 2016.[1][2]
According to the current US prescribing information (DailyMed, effective September 14, 2026), osimertinib is indicated for adults with non-small cell lung cancer (NSCLC) whose tumours carry specific EGFR mutations detected by an FDA-approved test:[1]
The indications below summarise the cited official Tagrisso/osimertinib information. They do not establish an approved indication for any other product listed on this page.
Approved uses, contraindications, warnings and monitoring requirements differ between countries. Whether osimertinib is suitable, and at what dose, is decided by the treating oncology team:
This directory is not a complete prescribing or safety guide. Serious risks, interactions and monitoring requirements apply. Consult the current official product information and the treating oncology team.
The products below are included for identification and availability-enquiry purposes. Inclusion does not mean that a product is authorised, approved, therapeutically equivalent or available in every country. Confirm regulatory status with the relevant national medicines authority.
A listed strength is not a dosing recommendation. Treatment, dose and duration must be decided by the treating physician.
Products are listed in alphabetical order. The list is not a ranking and makes no claim that one product is better than another.[3]
No product matches these filters.
Product listing data last checked September 24, 2026.
Tagrisso is the originator osimertinib medicine. It is marketed by AstraZeneca and was the first osimertinib product to be approved, by the US Food and Drug Administration in 2015. Other products represented as containing osimertinib are made by other manufacturers and sold under their own brand names.[1][2]
The originator is shown here separately from the other listed products.
This comparison covers identity and listing information only. It does not establish regulatory approval, pharmaceutical equivalence, bioequivalence, quality, safety or clinical effectiveness.
| Attribute | Other listed osimertinib products | Originator (Tagrisso) |
|---|---|---|
| Active substance | Osimertinib, as listed. The salt form is not stated in the product listings.[3] | Osimertinib (osimertinib mesilate in the EU product)[2] |
| Brand name | Each manufacturer's own brand name (14 products listed)[3] | Tagrisso[1] |
| Company | 14 different manufacturers, as listed[3] | AstraZeneca[1][2] |
| Dosage form | Tablet, as listed[3] | Film-coated tablet[1] |
| Strengths | 80 mg; 40 mg also listed for Osimatab and Tasso[3] | 40 mg and 80 mg (US label)[1] |
| Regulatory approval | Varies by product and country. Not independently verified for this page; check with your national medicines authority. | US FDA approval 2015 · EU authorisation 2016[1][2] |
| Classification | Product represented by its manufacturer or supplier as containing osimertinib. Regulatory classification must be confirmed in the relevant jurisdiction.[3] | Originator product[1][2] |
Tell us your country and the product information you are looking for.
Medicine for World may assess whether it can support a request for the destination country. If further documentation is needed, it will be requested separately; do not send it through this form.
If the request can lawfully be supported, you may receive current product information, availability and a quotation.
Any transaction is subject to prescription requirements, supplier checks, local law, import rules and final confirmation.
Submitting an enquiry does not guarantee availability, regulatory eligibility, import permission, delivery or a transaction.
Submit a non-binding enquiry. Medicine for World may assess whether it can support the request for your destination country. Do not send sensitive medical documents through this form.
This service cannot assist with medical emergencies or treatment decisions. Contact your treating healthcare professional or local emergency service.
Osimertinib is a prescription-only kinase inhibitor that acts on the epidermal growth factor receptor (EGFR). The US prescribing information lists it for adults with certain EGFR-mutated non-small cell lung cancers. The originator medicine is Tagrisso by AstraZeneca.
14 products represented by their manufacturers or suppliers as containing osimertinib: Irmukin, LuciOsim, Osicent, Osiem, Osikin, Osimatab, Osimert, Osimitib, Osinib, Ositag, Osmigen, Oysiendx, Tagribo, and Tasso. It is not a complete global list, and inclusion does not mean a product is authorised or approved in any specific country.
Tagrisso, marketed by AstraZeneca. It was first approved in the United States in 2015 and authorised in the European Union in 2016.
All listed products are tablets. Every listed product includes 80 mg; Osimatab and Tasso are also listed at 40 mg. The US label for Tagrisso covers 40 mg and 80 mg tablets. These are product strengths, not dosing recommendations.
This page does not establish regulatory approval, pharmaceutical equivalence, bioequivalence, quality, safety or clinical effectiveness for any listed product. Confirm regulatory status with the relevant national medicines authority.
This page does not rank or compare products and makes no claim about relative effectiveness or quality. The choice of medicine should be made with the treating doctor.
Submit a non-binding enquiry using the form on this page. Enquiries are handled by Medicine for World. Prices are not published; current information and a quotation are provided only if the request can lawfully be supported.
Initially only your name, country and one contact method. If further documentation is needed, Medicine for World may request it separately. Do not send medical documents through this form.
MedFactHub is a commercial affiliate and referral website for Medicine for World. Availability enquiries are handled by Medicine for World, which may receive commercial benefit from a resulting transaction.
No. It gives information about medicine identity and listed products. Decisions about treatment, dose and duration belong to a qualified healthcare professional.
Current editorial and medical-review status is shown below. No independent medical review is claimed until it has been completed.
Medical and regulatory facts come from official product information. Product listing details come from a supplied dataset. Numbers in square brackets on this page refer to the sources below.